| 1 | Targeting PI3K/Akt/mTOR Signaling in Cancer | Frontiers in Oncology | 2014 | 1,306 |
| 2 | Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations | Frontiers in Oncology | 2018 | 1,191 |
| 3 | Role of Matrix Metalloproteinases in Angiogenesis and Cancer | Frontiers in Oncology | 2019 | 858 |
| 4 | Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches | Frontiers in Oncology | 2019 | 776 |
| 5 | Targeting PI3K/mTOR Signaling in Cancer | Frontiers in Oncology | 2014 | 747 |
| 6 | The role of BCL-2 family proteins in regulating apoptosis and cancer therapy | Frontiers in Oncology | 2022 | 707 |
| 7 | Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis | Frontiers in Oncology | 2015 | 653 |
| 8 | Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi | Frontiers in Oncology | 2018 | 602 |
| 9 | Radiation-induced brain injury: A review | Frontiers in Oncology | 2012 | 580 |
| 10 | Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy | Frontiers in Oncology | 2019 | 561 |
| 11 | Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice | Frontiers in Oncology | 2020 | 543 |
| 12 | Tumor-Associated Macrophages: Recent Insights and Therapies | Frontiers in Oncology | 2020 | 542 |
| 13 | Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer | Frontiers in Oncology | 2012 | 510 |
| 14 | The KEAP1–NRF2 System in Cancer | Frontiers in Oncology | 2017 | 488 |
| 15 | Chemical and Pharmacological Aspects of Caffeic Acid and Its Activity in Hepatocarcinoma | Frontiers in Oncology | 2019 | 470 |
| 16 | Targeting Macrophages in Cancer: From Bench to Bedside | Frontiers in Oncology | 2018 | 455 |
| 17 | CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future | Frontiers in Oncology | 2020 | 452 |
| 18 | PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? | Frontiers in Oncology | 2022 | 449 |
| 19 | Mitochondrial Dysfunction in Cancer | Frontiers in Oncology | 2013 | 435 |
| 20 | DNA Methyltransferases: A Novel Target for Prevention and Therapy | Frontiers in Oncology | 2014 | 435 |
| 21 | Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification | Frontiers in Oncology | 2017 | 426 |
| 22 | Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches | Frontiers in Oncology | 2022 | 425 |
| 23 | Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis | Frontiers in Oncology | 2020 | 424 |
| 24 | Ultra-High Dose Rate (FLASH) Radiotherapy: Silver Bullet or Fool's Gold? | Frontiers in Oncology | 2020 | 408 |
| 25 | Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research | Frontiers in Oncology | 2013 | 405 |
| 26 | Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications | Frontiers in Oncology | 2018 | 405 |
| 27 | PTEN: Multiple Functions in Human Malignant Tumors | Frontiers in Oncology | 2015 | 401 |
| 28 | The Global Landscape of EBV-Associated Tumors | Frontiers in Oncology | 2019 | 394 |
| 29 | Cancer-Associated Fibroblasts as Another Polarized Cell Type of the Tumor Microenvironment | Frontiers in Oncology | 2014 | 390 |
| 30 | Radiomic Machine-Learning Classifiers for Prognostic Biomarkers of Head and Neck Cancer | Frontiers in Oncology | 2015 | 380 |
| 31 | The Multidisciplinary Team (MDT) Approach and Quality of Care | Frontiers in Oncology | 2020 | 372 |
| 32 | Microtubules and Their Role in Cellular Stress in Cancer | Frontiers in Oncology | 2014 | 371 |
| 33 | Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer | Frontiers in Oncology | 2018 | 363 |
| 34 | “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway | Frontiers in Oncology | 2018 | 356 |
| 35 | Altered Tumor-Cell Glycosylation Promotes Metastasis | Frontiers in Oncology | 2014 | 354 |
| 36 | Radiation-Induced Oral Mucositis | Frontiers in Oncology | 2017 | 350 |
| 37 | Recent Advances in the Treatment of Breast Cancer | Frontiers in Oncology | 2018 | 348 |
| 38 | The Keap1–Nrf2 system in cancers: stress response and anabolic metabolism | Frontiers in Oncology | 2012 | 347 |
| 39 | Exploratory Study to Identify Radiomics Classifiers for Lung Cancer Histology | Frontiers in Oncology | 2016 | 344 |
| 40 | Fluorescence-Guided Surgery | Frontiers in Oncology | 2017 | 344 |
| 41 | Cell Adhesion and Matrix Stiffness: Coordinating Cancer Cell Invasion and Metastasis | Frontiers in Oncology | 2018 | 342 |
| 42 | The Role of the Extracellular Matrix and Its Molecular and Cellular Regulators in Cancer Cell Plasticity | Frontiers in Oncology | 2018 | 339 |
| 43 | Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers | Frontiers in Oncology | 2020 | 338 |
| 44 | Endoplasmic Reticulum Stress, Unfolded Protein Response, and Cancer Cell Fate | Frontiers in Oncology | 2017 | 337 |
| 45 | The role of IL-6/JAK2/STAT3 signaling pathway in cancers | Frontiers in Oncology | 2022 | 332 |
| 46 | Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy | Frontiers in Oncology | 2018 | 331 |
| 47 | Resistance Mechanisms to Anti-angiogenic Therapies in Cancer | Frontiers in Oncology | 2020 | 325 |
| 48 | Radiation-Induced Lung Injury (RILI) | Frontiers in Oncology | 2019 | 314 |
| 49 | Chronic Stress Promotes Cancer Development | Frontiers in Oncology | 2020 | 313 |
| 50 | Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis | Frontiers in Oncology | 2018 | 307 |